Skip to content
Screener

Interest Income at other companies

Arvinas logo
ArvinasARVN
$6.4M-45.3%
Septerna, Inc. logo
Septerna, Inc.SEPN
$5.03M+12.8%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$8.74M+11.5%
Regenxbio logo
RegenxbioRGNX
$1.22M-63.8%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemThree Months Ended May 31, 2026Three Months Ended May 31, 2025Six Months Ended May 31, 2026Six Months Ended May 31, 2025
General and administrative15,59414,28230,20525,936
Total operating expenses103,24792,378201,994173,695
Loss from operations(94,204)(48,322)(186,699)(111,186)
Interest and other income, net4,3985,6189,71912,131
Loss before income taxes(89,806)(42,704)(176,980)(99,055)
Provision for (benefit from) income taxes(271)760(271)760
Net loss$(89,535)$(43,464)$(176,709)$(99,815)
Net loss per share, basic and diluted$(0.81)$(0.52)$(1.60)$(1.19)

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s interest income?
Nurix Therapeutics, Inc. (NRIX) reported interest income of $4.4M in Q1 2026.
How has Nurix Therapeutics, Inc.'s interest income changed year-over-year?
Nurix Therapeutics, Inc.'s interest income decreased by 21.7% year-over-year, from $5.62M to $4.4M.
What is the long-term trend for Nurix Therapeutics, Inc.'s interest income?
Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s interest income has grown at a 127.3% compound annual growth rate (CAGR), from $823K to $21.97M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Nurix Therapeutics, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude